INFINITY PHARMACEUTICALS INC. : Infinity Reports Second Quarter 2013 …4-traders (press release)… of a Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg BID in approximately 120 patients wit…
Oncobiologics and InVentive Health Clinical Form Biosimilars PactPharmaceutical Technology MagazineThe current biosimilar assets include generic versions of Humira (adalimumab), Rituxan (rituximab), Avastin (bevacizumab), Herceptin (trastuzumab), and E…
SPECTRUM PHARMACEUTICALS, INC. : Spectrum Pharmaceuticals Reports …4-traders (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined …
Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic …7thSpace Interactive (press release)Exclusion criteria included disease exacerbation within past 30 days; rituximab or cyclophosphamide within 6 months; pregnancy. Vaccine …
|
Mainstreaming ME Research: The 8th Invest in ME International ME Conference …
ProHealth For it’s the growing recognition that immune treatments like Rituximab and Ampligen are having dramatic effects on many patients who were once bedbound and without hope, together with two decades of often confusing but highly suggestive research … |
|
Oakland County cancer doctor accused of unnecessary treatments, defrauding …
Detroit Free Press In one case, the federal complaint outlines, Fata prescribed 56 doses of rituximab to a non-Hodgkin’s lymphoma patient over two years, when the norm would be a dozen in two years. In another instance cited in the complaint, Fata allegedly forced a sick … |
|
Top Rated Report : Global Evolving Market for Biosimilar Opportunities …
SBWire (press release) In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), … |
|
Roche’s Avastin remains most requested drug in UK’s cancer drugs fund
PMLiVE Completing the top five most requested drugs were Roche’s MabThera (rituximab), which had 5.3 per cent of all requests (about 572) and GlaxoSmithKline’s Tyverb (lapatinib), which had 5.2 per cent of all requests (about 561). The ten most commonly used … |
|
An Interview With Dr. Dan Peterson
ProHealth A new area I’m excited about is the cytokine blockers and the immune modulator rituximab, which has gotten lot of press. Hopefully, they will do a much larger rituximab study in the near future. My concern with rituximab is that I don’t know how to … |
Economic Times |
DIPP may seek information from DCGI to manufacture generic version of …
Economic Times Indian companies have already developed biological products such as rituximab and pegylated interferon. There are several manufacturers who have trastuzumab in the pipeline as well,” said Leena Menghaney of Medecins Sans Frontieres, an international … |